Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an announcement.
BioDlink International Company Limited reported a 6% decrease in operating revenue for the first half of 2025, attributed to intensified competition and delayed project milestones. Despite a significant 87% drop in net profit, the company expanded its international presence with Bevacizumab injection approvals in Nigeria and Pakistan, and GMP inspections passed in several countries. The company also authorized Zhaoke Ophthalmology Limited as the marketing authorization holder for TAB014 in China, marking a strategic move in the ophthalmic drug market.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited, incorporated in Hong Kong, operates in the biopharmaceutical industry. The company focuses on the development and commercialization of pharmaceutical products, with a particular emphasis on Bevacizumab injection, marketed in China as Pusintin®, and TAB014 for treating wet age-related macular degeneration (wAMD).
Average Trading Volume: 259,830
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.99B
For a thorough assessment of 1875 stock, go to TipRanks’ Stock Analysis page.